Medxy AI – Page 15

KEYNOTE-585 vs MATTERHORN in Gastric Cancer: Insights from Divergent Trial Outcomes

Clinical Updates Wellness & Lifestyle

KEYNOTE-585 vs MATTERHORN in Gastric Cancer: Insights from Divergent Trial Outcomes

By MedXY 09/09/2025

The KEYNOTE-585 trial adding pembrolizumab to perioperative chemotherapy did not significantly improve event-free survival in esophagogastric cancer, while the MATTERHORN trial showed durvalumab plus FLOT chemotherapy improves outcomes, establishing a new standard of care.

Unraveling the Prognostic Impact of Co-Occurring High-Risk Cytogenetic Abnormalities in Multiple Myeloma

Clinical Updates Wellness & Lifestyle

Unraveling the Prognostic Impact of Co-Occurring High-Risk Cytogenetic Abnormalities in Multiple Myeloma

By MedXY 09/09/2025

A meta-analysis of 24 trials involving 13,926 patients establishes that concurrent high-risk cytogenetic abnormalities markedly worsen progression-free and overall survival in both newly diagnosed and relapsed multiple myeloma, underscoring the need for targeted therapeutic strategies.

Promising Frontline Triplet Therapies for IDH-Mutated AML Patients Ineligible for Intensive Chemotherapy

Clinical Updates Wellness & Lifestyle

Promising Frontline Triplet Therapies for IDH-Mutated AML Patients Ineligible for Intensive Chemotherapy

By MedXY 09/09/2025

Triplet regimens combining hypomethylating agents, venetoclax, and IDH inhibitors demonstrate high remission rates and survival in intensive chemotherapy-ineligible IDH-mutant AML patients, warranting further comparative studies against approved doublet therapies.

Prolonged Hospitalization Post-Hematopoietic Cell Transplantation: Identifying Risk Factors and Impacts on Patient Outcomes

Clinical Updates Wellness & Lifestyle

Prolonged Hospitalization Post-Hematopoietic Cell Transplantation: Identifying Risk Factors and Impacts on Patient Outcomes

By MedXY 09/09/2025

This study reveals that prolonged hospitalization after hematopoietic cell transplantation correlates with worse quality of life, greater symptom burden, increased depressive symptoms, and higher risk of rehospitalization and mortality within one year post-transplant.

Multisite Randomized Trial of Inpatient Palliative Care in Hematopoietic Stem Cell Transplantation: Enhancing Patient and Caregiver Outcomes

Clinical Updates Wellness & Lifestyle

Multisite Randomized Trial of Inpatient Palliative Care in Hematopoietic Stem Cell Transplantation: Enhancing Patient and Caregiver Outcomes

By MedXY 09/09/2025

Inpatient palliative care during hematopoietic stem cell transplantation improves patients’ quality of life, reduces depression and PTSD symptoms, and offers sustained psychological benefits up to six months post-transplant.

$Lisocabtagene Maraleucel: Transforming Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma — Insights from the 3-Year TRANSFORM Study Follow-Up$

Clinical Updates Wellness & Lifestyle

Lisocabtagene Maraleucel: Transforming Second-Line Therapy in Relapsed/Refractory Large B-Cell Lymphoma — Insights from the 3-Year TRANSFORM Study Follow-Up

By MedXY 09/09/2025

The 3-year follow-up of the phase III TRANSFORM study demonstrates that lisocabtagene maraleucel (liso-cel) provides superior durable efficacy and a favorable safety profile compared with standard of care in second-line relapsed/refractory large B-cell lymphoma.

Breastfeeding After Hormone Receptor-Positive Breast Cancer: Insights From the POSITIVE Trial

Clinical Updates Wellness & Lifestyle

Breastfeeding After Hormone Receptor-Positive Breast Cancer: Insights From the POSITIVE Trial

By MedXY 09/09/2025

The POSITIVE trial reveals that two thirds of women with early hormone receptor-positive breast cancer successfully breastfed post-treatment, without a significant increase in cancer recurrence risk, offering reassurance to women considering pregnancy and breastfeeding after breast cancer.

ADAGIO Trial Illuminates Adavosertib’s Potential in Recurrent Uterine Serous Carcinoma Amidst Safety Challenges

Clinical Updates Wellness & Lifestyle

ADAGIO Trial Illuminates Adavosertib’s Potential in Recurrent Uterine Serous Carcinoma Amidst Safety Challenges

By MedXY 09/09/2025

The ADAGIO phase IIb study assessed adavosertib in recurrent uterine serous carcinoma post-platinum therapy, revealing modest efficacy and significant toxicity, with biomarker trends suggesting CCNE1/cyclin E1 as potential response predictors.

$Potential Curative Impact of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Five-Year Outcomes from CARTITUDE-1$

Clinical Updates Wellness & Lifestyle

Potential Curative Impact of Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma: Five-Year Outcomes from CARTITUDE-1

By MedXY 09/09/2025

CARTITUDE-1 demonstrates that a single infusion of ciltacabtagene autoleucel (cilta-cel) yields durable ≥5-year remission and extended survival in heavily pretreated relapsed/refractory multiple myeloma, with compelling MRD negativity and a favorable safety profile.

Long-Term Real-World Outcomes of Adjuvant Anti-PD-1 Checkpoint Inhibition Versus Targeted Therapy in Stage III Melanoma: A Comprehensive Review

Clinical Updates Wellness & Lifestyle

Long-Term Real-World Outcomes of Adjuvant Anti-PD-1 Checkpoint Inhibition Versus Targeted Therapy in Stage III Melanoma: A Comprehensive Review

By MedXY 09/09/2025

This review synthesizes current evidence on long-term real-world efficacy of adjuvant anti-PD-1 immunotherapy and targeted BRAF/MEK inhibitor therapy in stage III melanoma, highlighting differential recurrence risks, survival benefits, and treatment duration implications.

Improving Outcomes in Mismatched Unrelated Donor Stem Cell Transplants With Post-Transplant Cyclophosphamide

Clinical Updates Wellness & Lifestyle

Improving Outcomes in Mismatched Unrelated Donor Stem Cell Transplants With Post-Transplant Cyclophosphamide

By MedXY 09/09/2025

Post-transplant cyclophosphamide (PTCy) for graft-versus-host disease prophylaxis significantly improves 1-year survival and lowers severe GVHD rates in mismatched unrelated donor peripheral blood stem cell transplants, expanding access for underrepresented patient groups.

Patritumab Deruxtecan: A Promising New Hope in Advanced Non-Small Cell Lung Cancer Post Platinum and Immunotherapy

Clinical Updates Wellness & Lifestyle

Patritumab Deruxtecan: A Promising New Hope in Advanced Non-Small Cell Lung Cancer Post Platinum and Immunotherapy

By MedXY 09/08/2025

Patritumab deruxtecan (HER3-DXd) demonstrates notable efficacy and manageable safety in heavily pretreated advanced NSCLC, including patients without EGFR mutations, offering a potential new treatment avenue.

Avutometinib Plus Defactinib: A Promising Treatment for Recurrent Low-Grade Serous Ovarian Cancer

Clinical Updates Wellness & Lifestyle

Avutometinib Plus Defactinib: A Promising Treatment for Recurrent Low-Grade Serous Ovarian Cancer

By MedXY 09/08/2025

This phase II study demonstrates that the combination of avutometinib and defactinib offers significant clinical benefit with manageable safety in recurrent low-grade serous ovarian cancer, particularly in KRAS-mutant tumors.

Efficacy and Challenges of Pazopanib in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from the Alliance A021202 Trial

Clinical Updates Wellness & Lifestyle

Efficacy and Challenges of Pazopanib in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from the Alliance A021202 Trial

By MedXY 09/08/2025

The randomized phase II Alliance A021202 trial demonstrated that pazopanib significantly improves progression-free survival in advanced extrapancreatic neuroendocrine tumors, confirming VEGF pathway as a therapeutic target but highlighting safety concerns that preclude further development.

Xevinapant Fails to Improve Outcomes in Locally Advanced Head and Neck Cancer: Insights from the Phase III TrilynX Trial

Clinical Updates Wellness & Lifestyle

Xevinapant Fails to Improve Outcomes in Locally Advanced Head and Neck Cancer: Insights from the Phase III TrilynX Trial

By MedXY 09/08/2025

The TrilynX phase III study showed that adding xevinapant to platinum-based chemoradiotherapy did not improve event-free survival and was associated with worse overall survival and higher toxicity in unresected locally advanced squamous cell carcinoma of the head and neck.

Revolutionizing Early Detection of Pancreatic Cancer: A cfDNA Fragmentomics and Machine Learning Model

Clinical Updates Wellness & Lifestyle

Revolutionizing Early Detection of Pancreatic Cancer: A cfDNA Fragmentomics and Machine Learning Model

By MedXY 09/08/2025

A new cell-free DNA fragmentomics model combined with machine learning achieves high accuracy for early pancreatic cancer detection, potentially improving patient outcomes through timely intervention.

Neoadjuvant Osimertinib in Resectable EGFR-Mutated NSCLC: Advancing Preoperative Therapeutics

Clinical Updates Wellness & Lifestyle

Neoadjuvant Osimertinib in Resectable EGFR-Mutated NSCLC: Advancing Preoperative Therapeutics

By MedXY 09/08/2025

Neoadjuvant osimertinib, alone or with chemotherapy, significantly improves major pathological response rates in resectable EGFR-mutated NSCLC, offering a promising approach to enhance surgical outcomes and event-free survival with an acceptable safety profile.

AI Revolutionizing Pharma: From Drug Discovery to Clinical Application Through Intelligent Innovation

Clinical Updates Wellness & Lifestyle

AI Revolutionizing Pharma: From Drug Discovery to Clinical Application Through Intelligent Innovation

By MedXY 09/08/2025

Artificial intelligence is dramatically transforming pharmaceutical R&D by accelerating drug discovery, formulation, and clinical trials, while presenting new opportunities and challenges for the industry, especially in China.

Bridging the Gap: Addressing Inconsistent Reporting of Venous and Arterial Thrombotic Events in Cancer Clinical Trials

Clinical Updates Wellness & Lifestyle

Bridging the Gap: Addressing Inconsistent Reporting of Venous and Arterial Thrombotic Events in Cancer Clinical Trials

By MedXY 09/08/2025

Venous and arterial thrombotic events in cancer patients are underreported in clinical trials, impairing risk assessment and prevention strategies. Uniform and comprehensive reporting is imperative to improve patient outcomes and guide therapeutic decisions.

Rapamycin and Aging: Insights from the PEARL Trial on Safety and Healthspan Enhancements After One Year

Clinical Updates Wellness & Lifestyle

Rapamycin and Aging: Insights from the PEARL Trial on Safety and Healthspan Enhancements After One Year

By MedXY 09/08/2025

The PEARL trial demonstrates that low-dose, intermittent rapamycin is safe in healthy aging adults and improves lean tissue mass and pain in women, with additional benefits in emotional well-being and general health at lower doses.

Clinical Updates Wellness & Lifestyle

Immunogenicity and Safety of the VLA15 Lyme Borreliosis Vaccine Across Age Groups: A Phase 2 Randomised Controlled Trial and Integrative Review

By MedXY 09/21/2025

Clinical Updates Wellness & Lifestyle

MACRO Trial Insights: Endoscopic Sinus Surgery Outperforms Clarithromycin in Chronic Rhinosinusitis Management

By MedXY 09/21/2025

Clinical Updates Wellness & Lifestyle

Adjunctive Corticosteroids in Severe Pneumocystis jirovecii Pneumonia Among HIV-negative Patients: Insights from a Multicentre Randomised Trial

By MedXY 09/21/2025

Clinical Updates Wellness & Lifestyle

Evaluating BDLC Regimen in Pre-XDR Tuberculosis: Findings from the endTB-Q Phase 3 Trial

By MedXY 09/21/2025